Related Experiment Videos
Commentary on 'Alpha calculus in clinical trials: considerations and commentary for the new millennium'
1Food and Drug Administration, Center for Drug Evaluation and Review, Office of Biostatistics, 5600 Fishers Lane, Parklawn Building, Room 15B-45, Rockville, MD 20857, USA.
Statistics in Medicine
|March 29, 2000
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
Clinical pharmacology and therapeutics·2013
The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.
Clinical pharmacology and therapeutics·2012
FDA's critical path initiative: a perspective on contributions of biostatistics.
Biometrical journal. Biometrische Zeitschrift·2006
Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance.
Controlled clinical trials·1997
The Cox-Aalen Rate Model for Recurrent Events With an Informative Terminal Event.
Statistics in medicine·2026
ReMeDy: A Flexible Statistical Framework for Region-Based Detection of DNA Methylation Dysregulation.
Statistics in medicine·2026
An Assessment of Reliability Estimation Methods for Binomial Health Care Quality Measures.
Statistics in medicine·2026
Family-Wise Error Rate Control in Clinical Trials With Overlapping Populations.
Statistics in medicine·2026
A Bayesian Spatiotemporal Model for Joint Estimation of Brain Activation and Connectivity in fMRI Studies.
Statistics in medicine·2026